Successful treatment with bortezomib for refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus-Reference-Cited by-同舟云学术

Successful treatment with bortezomib for refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus

Published:2022-12-01 Issue:4 Volume:3 Page:208-210
ISSN:2719-4523
Container-title:Rheumatology and Immunology Research
language:en
Short-container-title:

Author:

Yan Ruyu¹²,Zhou Shuang¹,Wang Jinuo¹,Yang Huaxia¹

Affiliation:

1. Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, The Ministry of Education Key Laboratory , Beijing 100730 , China

2. Department of Rheumatology, The Second Affiliated Hospital, Chongqing Medical University , Chongqing 400010 , China

Abstract

Abstract Thrombotic thrombocytopenic purpura (TTP) is a life- threatening disease that can be secondary to systemic lupus erythematosus (SLE). The fist- line treatments of TTP are steroid, immunosuppressor and plasm exchange (PE). However, some patients may have a poor response to these treatments. Bortezomib is a selective proteasome inhibitor and widely used to treat patients with multiple myeloma (MM). In recent years, bortezomib has been used to treat patients with refractory TTP. Here we report a patient with refractory TTP associated with SLE and had a successful treatment with bortezomib.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.2478/rir-2022-0036/pdf

Reference7 articles.

1. Letchumanan P, Ng HJ, Lee LH, et al. A Comparison of Thrombotic Thrombocytopenic Purpura in an Inception Cohort of Patients with and without Systemic Lupus Erythematosus. Rheumatology (Oxford). 2009;48:399–403.

2. Kwok SK, Ju JH, Cho CS, et al. Thrombotic Thrombocytopenic Purpura in Systemic Lupus Erythematosus: Risk Factors and Clinical Outcome: A Single Centre Study. Lupus. 2009;18:16–21.

3. Gungor T, Furlan M, Lammle B, et al. Acquired Deficiency of Von Willebrand Factor-Cleaving Protease in a Patient Suffering from Acute Systemic Lupus Erythematosus. Rheumatology (Oxford). 2001;40:940–942.

4. Neubert K, Meister S, Moser K, et al. The Proteasome Inhibitor Bortezomib Depletes Plasma Cells and Protects Mice with Lupus-Like Disease from Nephritis. Nat Med. 2008;14:748–755.

5. Patriquin CJ, Thomas MR, Dutt T, et al. Bortezomib in the Treatment of Refractory Thrombotic Thrombocytopenic Purpura. Br J Haematol. 2016;173:779–785.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma cell‐directed therapy strategies in immune‐mediated thrombotic thrombocytopenic purpura (iTTP);Transfusion;2024-01-18

2. Thrombotic thrombocytopenic purpura that developed 3 years after systemic lupus erythematosus had remitted with rituximab therapy;Modern Rheumatology Case Reports;2023-06-10